Metastatic castration-resistant prostate cancer (mCRPC)

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

January, 2025

Metastatic castration-resistant prostate cancer (mCRPC)

Oct 13, 2024, 06:09 | Blog

The LATITUDE study of men with high-risk metastatic castration-resistant prostate cancer

International Institute of Urology Journal shared a post on X: '' In this issue of…

Aug 10, 2024, 12:17 | Insight

Emmanuel Antonarakis: Most compelling study suggesting that combined Abiraterone and Olaparib is better than sequential Abiraterone and Olaparib for 1st-line mCRPC

Emmanuel Antonarakis, Professor of Medicine at the University of Minnesota, shared a post on X…

Jul 11, 2024, 10:12 | Blog

Shilpa Gupta: Stellar talk by Neeraj Agarwal on tremendous progress in mCRpC in Athens

Shilpa Gupta shared a post on X: “Stellar talk by Neeraj Agarwal on tremendous progress…

All: 3 Posts: 1 - 100

'

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

'

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

'

Best of ASCOGI25

'

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

'

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023